Commentary|Articles|August 10, 2026

The AUA Clinically Localized Prostate Cancer guideline: FAQs for urologists

Fact checked by: Benjamin P. Saylor, Strategic Content Lead

These FAQs highlight key recommendations and practical takeaways from the 2026 AUA/ASTRO Clinically Localized Prostate Cancer guideline amendment.

The American Urological Association (AUA)'s guideline on clinically localized prostate cancer was amended in 2026 to sharpen its recommendations on risk stratification, staging, and risk-based management, while incorporating new evidence on imaging and systemic therapy intensification for higher-risk disease.¹ The updates touch nearly every stage of the care pathway, from how patients are risk-stratified at diagnosis through how they are followed after treatment.